CriticalFirst-generation antipsychotic, aliphatic-side-chain phenothiazine×Prokinetic, peripheral dopamine D2 receptor antagonist
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Chlorpromazine belongs to the phenothiazine neuroleptics, which can intensify QT prolongation. This raises the risk of serious ventricular arrhythmias of the torsade de pointes type, which can end in sudden death. QT prolongation is a common adverse reaction of chlorpromazine (chlorpromazine SmPC, AEMPS). According to the Spanish chlorpromazine SmPC, the risk of arrhythmias rises with QT-prolonging drugs. The domperidone SmPC explains its contraindication of such combinations by a higher risk of QT prolongation through pharmacodynamic or pharmacokinetic interactions (chlorpromazine and domperidone SmPCs, AEMPS). The liver metabolises domperidone mainly through CYP3A4, while chlorpromazine strongly inhibits a different enzyme, CYP2D6 (domperidone and chlorpromazine SmPCs, AEMPS). The documents give no data on how one drug changes the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With chlorpromazine, QT prolongation that can trigger a ventricular arrhythmia is a common adverse reaction, and ventricular fibrillation, ventricular tachycardia, torsade de pointes, cardiac arrest and sudden death have also been reported (chlorpromazine SmPC, AEMPS). QT prolongation gets worse in particular with a slow heart rate, low potassium, and congenital or drug-induced QT prolongation (chlorpromazine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs, without a closed list, and according to its own SmPC chlorpromazine belongs to this group (domperidone and chlorpromazine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish chlorpromazine SmPC does not recommend combining chlorpromazine with other QT-prolonging drugs either (chlorpromazine SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Before starting chlorpromazine, when the clinical situation allows, rule out risk factors for arrhythmia: a heart rate below 55 beats per minute, low potassium, congenital QT prolongation, and current use of drugs that can cause marked bradycardia, low potassium, slowed conduction in the heart or QT prolongation (chlorpromazine SmPC, AEMPS). Except in emergencies, the SmPC recommends an electrocardiogram (ECG) as part of the initial assessment before neuroleptic treatment (chlorpromazine SmPC, AEMPS). If domperidone and chlorpromazine have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Clorpromazina (nº registro 42934), sección 4.4 (2023)– AEMPS, CIMA, nº registro 42934 (Largactil 100 mg comprimidos recubiertos con película, Neuraxpharm Spain), revisión 07/2023, secciones 4.3, 4.4, 4.5, 4.8 y 5.2